思力华安全性和疗效获最大型慢阻肺临床试验证实

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposes the use of long-acting bronchodilators to treat patients with stable chronic obstructive pulmonary disease (COPD). Among them, anticholinergic drugs are the preferred drugs, which exert their effect by competing with endogenous choline in the body for cholinergic receptors. Cholinergic receptor blockers such as ipratropium bromide and tiotropium bromide mainly block M3 receptors. The new tiotropium bromide spray (Spiriva Respimat,) is a new drug that has been on the market in recent years. Its soft mist inhaler is a new generation of propellant-free inhaler. In this type of inhalation device, inhalable droplets are generated from aqueous solution. The size and speed of the droplets allow the drug aerosol to be deposited into the patient's lungs, bringing good inhalation effects and being used by many COPD patients. Recently, the safety and efficacy of Slivia were confirmed by the largest COPD clinical trial.

The clinical data of 280 patients with chronic obstructive pulmonary disease admitted to the Department of Respiratory Medicine were analyzed and divided into groups according to different treatment methods, with 140 cases in the control group (given basic treatment) and 140 cases in the experimental group (given treatment with Slivar Respimat). The results suggest that Slivar Respimat can reduce the level of pulmonary hypertension in patients with COPD, improve blood oxygen partial pressure, improve exercise tolerance, and can also reduce inflammatory factors in the serum, which is beneficial to the improvement of clinical symptoms.

TIOSPIR is a large international study involving more than 17,000 patients and is the largest chronic obstructive pulmonary disease (COPD) trial to date. Participants were randomly assigned to receive treatment at more than 1,200 research centers in 50 countries. The TIOSPIR trial showed that the test doses of 5 μg and 2.5 μg of Sliva nebulizer are the same as Sliva 18 μg in terms of safety and efficacy for COPD attacks.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.